t
GSK plc notified the market on 24 July 2026 of the admission of 70,759 ordinary shares of 31¼ pence each to trading on the London Stock Exchange's Main Market. These shares, admitted between 29 May 2026 and 24 July 2026 under the GlaxoSmithKline plc Share Save Plan 2022, bring the total number of ordinary shares admitted to trading to 4,316,292,310.
Issued: 24 July 2026, London UK
Admission to trading
In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the "GlaxoSmithKline plc Share Save Plan 2022".
|
1a |
Issuer name
|
GSK plc |
|
1b |
Issuer LEI
|
5493000HZTVUYLO1D793 |
|
2 |
Regulated market on which the securities have been admitted to trading
|
London Stock Exchange - Main Market |
|
3 |
Name, type and ISIN of the securities |
Ordinary Shares of 31¼ pence each
ISIN: GB00BN7SWP63
|
|
4 |
Number of further securities admitted to trading covered by this notification
|
70,759 |
|
5 |
Total number of securities admitted to trading following admission
|
4,316,292,310 |
|
6 |
Fungibility
|
Fully fungible with existing Ordinary Shares |
|
7 |
Date range covered by the notification |
29 May 2026 - 24 July 2026
|
|
8 |
Prospectus information |
N/A
|
V A Whyte
Company Secretary
24 July 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG